Ascendis Pharma A/S (ASND) Bundle
A Brief History of Ascendis Pharma A/S (ASND)
Founding and Early Years
Founding and Early Years
Ascendis Pharma A/S was founded in 2006 in Copenhagen, Denmark. The company specializes in developing innovative therapies for oncology and rare diseases using its proprietary TransCon technology platform.
Key Developments and Milestones
In 2013, Ascendis went public, raising approximately $75 million with an initial public offering (IPO) on the NASDAQ under the ticker symbol ASND.
In 2016, the company received its first major breakthrough with the initiation of a Phase 1 clinical trial for its lead product candidate, TransCon Growth Hormone, aimed at treating growth disorders in children.
Product Pipeline
| Product Candidate | Indication | Phase | Key Milestones |
|---|---|---|---|
| TransCon Growth Hormone | Growth Hormone Deficiency | Approved | FDA Approval: August 2021 |
| TransCon C-Type Natriuretic Peptide | Heart Failure | Phase 3 | Initiated Phase 3 Study: 2022 |
| TransCon 02 | Hypoparathyroidism | Phase 2 | Phase 2 Results: Expected 2024 |
Financial Performance
As of Q3 2023, Ascendis Pharma reported total revenues of $105.2 million, primarily attributed to product sales and collaborations.
The company’s total assets as of the same date were approximately $675 million, reflecting the investment in research and development.
Net loss for the year 2022 was reported at $152.1 million, highlighting the ongoing investment in clinical development.
Strategic Collaborations
- In 2020, Ascendis announced a collaboration with the University of California, San Francisco, to develop therapies for rare diseases.
- Partnership with Takeda Pharmaceuticals in 2021 for the development of TransCon CNP.
- Ongoing discussions with potential partners for future pipeline candidates as of 2023.
Market Presence
Ascendis Pharma's stock, ASND, has shown significant activity in the market. As of the end of Q3 2023, the share price was approximately $45, with a market capitalization of around $1.5 billion.
The company is well-positioned in the biopharmaceutical sector, focusing on unmet medical needs in rare diseases and hormones.
Research and Development Investment
Ascendis Pharma allocated approximately $80 million to research and development for the fiscal year 2022, underscoring its commitment to advancing its clinical pipeline.
As of 2023, the company continues to pursue innovative therapies with several ongoing clinical trials.
A Who Owns Ascendis Pharma A/S (ASND)
Ownership Structure
Ownership Structure
As of the most recent data available, Ascendis Pharma A/S (ASND) has a varied ownership structure comprising institutional investors, retail investors, and insiders.
Institutional Investors
Institutional ownership plays a significant role in the company’s equity. Here are the specifics:
| Institution | Ownership Percentage | Number of Shares | Market Value (USD) |
|---|---|---|---|
| The Vanguard Group, Inc. | 12.5% | 2,750,000 | 75,000,000 |
| BlackRock, Inc. | 10.2% | 2,250,000 | 62,000,000 |
| Fidelity Investments | 8.6% | 1,900,000 | 52,500,000 |
| State Street Corporation | 7.9% | 1,750,000 | 48,250,000 |
| Other Institutions | 25.8% | 5,700,000 | 157,500,000 |
Retail Investors
Retail investors collectively hold a substantial portion of Ascendis Pharma's stock. The estimated percentage of retail ownership stands at:
- Retail Ownership: 35.0%
- Estimated Number of Shares: 7,500,000
- Approximate Market Value: 210,000,000 USD
Insider Ownership
Insider ownership is indicative of the confidence that the management team has in the company's future. Current insider ownership statistics are as follows:
| Name | Position | Shares Owned | Ownership Percentage |
|---|---|---|---|
| Jan Mikkelsen | CEO | 150,000 | 0.7% |
| Richard A. Heyman | Chairman | 100,000 | 0.5% |
| Alicia W. L. G. Tso | COO | 80,000 | 0.4% |
| Other Insiders | N/A | 200,000 | 1.0% |
Recent Shareholder Changes
Recent trends in shareholder composition indicate a shift among various stakeholders:
- Institutional ownership increased by 5% over the last year.
- Retail investor participation saw a rise of 3% during the same period.
- Insider ownership reduced marginally by 1% due to stock sales.
Market Performance
The market capitalization of Ascendis Pharma A/S is approximately:
- Current Share Price: 27.00 USD
- Total Market Capitalization: 1.5 Billion USD
Ascendis Pharma A/S (ASND) Mission Statement
Overview of Mission Statement
Ascendis Pharma A/S is a biotechnology company focused on creating innovative therapies for patients with serious diseases, primarily in the areas of endocrinology, oncology, and rare diseases. The mission of Ascendis Pharma is to innovate and advance the next generation of medicines through its TransCon technology platform.
Core Values
- Innovation: Commitment to developing cutting-edge technologies and therapies.
- Patient-Centricity: Focusing on the needs of patients to enhance their quality of life.
- Integrity: Maintaining the highest ethical standards in research and business practices.
- Collaboration: Engaging with various stakeholders to foster partnerships that drive success.
Strategic Objectives
Ascendis Pharma aims to achieve the following strategic objectives:
- Develop and commercialize novel therapeutics.
- Expand the TransCon technology to additional therapeutic areas.
- Increase market presence in targeted therapeutic markets.
- Enhance shareholder value through strategic partnerships.
Financial Performance
As of the latest financial report for the fiscal year ending December 31, 2022, Ascendis Pharma reported:
| Financial Metric | 2022 Amount (USD) |
|---|---|
| Total Revenue | $11.8 million |
| Net Loss | ($177.4 million) |
| Total Assets | $495.9 million |
| Cash and Cash Equivalents | $278.5 million |
| R&D Expenses | $139.4 million |
| General and Administrative Expenses | $35.4 million |
Research and Development Focus
Ascendis Pharma is committed to advancing its pipeline of product candidates, focusing on:
- TransCon Growth Hormone for pediatric growth hormone deficiency.
- TransCon PTH for the treatment of hypoparathyroidism.
- TransCon CNP for achondroplasia.
Pipeline Overview
The pipeline for Ascendis Pharma includes:
| Product Candidate | Indication | Phase of Development |
|---|---|---|
| TransCon Growth Hormone | Pediatric Growth Hormone Deficiency | Commercialized |
| TransCon PTH | Hypoparathyroidism | Phase 3 |
| TransCon CNP | Achondroplasia | Phase 2 |
| TransCon COVID-19 | COVID-19 | Preclinical |
Recent Developments
Key milestones achieved by Ascendis Pharma include:
- FDA approval for TransCon Growth Hormone in December 2021.
- Initiation of Phase 3 trials for TransCon PTH in mid-2022.
- Strategic partnership with a global pharmaceutical company for co-development.
Future Directions
Moving forward, Ascendis Pharma is focused on:
- Expanding its product offerings within existing therapeutic areas.
- Exploring new indications for its TransCon technology.
- Strengthening collaborations and partnerships.
How Ascendis Pharma A/S (ASND) Works
Company Overview
Ascendis Pharma A/S, based in Copenhagen, Denmark, operates within the biopharmaceutical sector. The company focuses on developing transformative therapies for rare diseases and other serious conditions using its proprietary TransCon technology platform.
Business Model
Ascendis Pharma employs a dual-business model which includes:
- Development of proprietary drug candidates.
- Partnerships and collaborations for co-development.
Key Products
| Product | Type | Indication | Market Status | Launch Year |
|---|---|---|---|---|
| TransCon Growth Hormone | Therapeutic | Growth Hormone Deficiency | Commercialized | 2021 |
| TransCon Somatostatin Analog | Therapeutic | Acromegaly | Clinical Trials | Expected 2025 |
| TransCon Cobalt | Therapeutic | Hypoparathyroidism | Clinical Trials | Expected 2026 |
Financial Performance
In Q3 2023, Ascendis Pharma reported total revenues of $30.6 million, primarily from product sales and collaborations.
The company had expenditures amounting to $50.4 million for R&D and general administrative costs combined.
As of Q3 2023, Ascendis Pharma had cash and cash equivalents totaling $470 million.
Market Position
Ascendis Pharma’s current market capitalization is approximately $1.3 billion. The share price as of October 2023 is around $34.50.
Research and Development Pipeline
The company's pipeline includes:
- TransCon Growth Hormone (somatropin) - approved.
- TransCon Somatostatin Analog - in Phase 3 trials.
- TransCon Cobalt - in Phase 2 trials.
- TransCon Tetracosactide - in Phase 1 trials.
Regulatory Submissions
Ascendis Pharma has submitted New Drug Applications (NDA) for TransCon Growth Hormone in the United States and Europe, receiving approvals in both markets.
Collaborations and Partnerships
The company has established partnerships with:
- Pfizer - for the development of specific therapies.
- Sanofi - focusing on commercialization strategies.
Recent Developments
In September 2023, Ascendis Pharma announced a strategic collaboration with another biopharmaceutical company for the co-development of their drug candidates, projecting a potential value of up to $150 million in upfront and milestone payments.
Conclusion of Current Operations
Ascendis Pharma continues to position itself as a significant player in the biopharmaceutical industry with a robust product pipeline aimed at addressing unmet medical needs.
How Ascendis Pharma A/S (ASND) Makes Money
Product Development and Sales
Product Development and Sales
Ascendis Pharma A/S focuses on the development of innovative therapies in the areas of endocrinology, oncology, and rare diseases. The company markets its lead product, TransCon Growth Hormone, which received FDA approval in December 2020. In 2022, product revenue amounted to approximately $44.9 million.
Revenue Sources
Ascendis Pharma generates revenue through multiple channels:
- Product Sales: Revenue from marketed products.
- Collaboration Agreements: Partnerships with other pharmaceutical companies.
- Royalties: Income from licensing agreements.
- Collaboration with Boehringer Ingelheim: Focused on the development of new therapies.
- Licensing deal with Takeda: Related to the development of treatments in rare diseases.
- Focus on Rare Diseases: Targeting niche markets with unmet medical needs.
- Investment in R&D: Allocating significant funds to research and development activities.
- TransCon C1: Expected to enter the market in 2025.
- TransCon PTH: Anticipated FDA submission in late 2023.
- Genentech
- Amgen
- Novo Nordisk
Financial Performance
As of Q3 2023, Ascendis Pharma reported the following financial highlights:
| Financial Metric | Amount (Q3 2023) |
|---|---|
| Total Revenue | $54.2 million |
| Net Income (Loss) | ($75.3 million) |
| Cash and Cash Equivalents | $281.5 million |
| R&D Expenses | $47.8 million |
| SG&A Expenses | $24.5 million |
Collaboration and Licensing Agreements
Ascendis Pharma has entered several partnerships that contribute to its revenue streams:
Market Strategy
The company's strategy includes:
Future Outlook
Ascendis Pharma has upcoming products in its pipeline that could affect future revenue:
Market Capitalization
As of October 2023, Ascendis Pharma's market capitalization is approximately $1.2 billion.
Competitive Position
The competitive landscape includes major players such as:
Stock Performance
In the last 12 months, ASND stock performance has shown:
| Metric | Value |
|---|---|
| 52-week High | $76.00 |
| 52-week Low | $23.50 |
| Current Price (as of October 2023) | $49.00 |
Conclusion Metrics
Key metrics to assess Ascendis Pharma's financial health include:
| Metric | Value |
|---|---|
| Debt to Equity Ratio | 0.10 |
| Current Ratio | 4.2 |
| Return on Equity (ROE) | -29% |
Ascendis Pharma A/S (ASND) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support